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Dual role of the activated 
epidermal growth factor 
receptor in renal tubular cells 
during stress
I Arany1
The paper by Sarro et al. raises the therapeutically important 
possibility that activation of the epidermal growth factor receptor 
(EGFR) after proximal tubule injury serves an unexpected death 
function and the EGFR-mediated survival signaling can be restored 
by identification of parallel and interacting pathways.
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In this issue of Kidney International, Sarro 
et al.1 demonstrate that nephrotoxic-
ity induced by the immunosuppressor 
cyclosporine A (CsA) is intimately linked 
to the activated epidermal growth factor 
receptor (EGFR) in mouse proximal tubule 
cells in vitro. The paper calls attention to a 
long-disregarded fact: the activated EGFR 
could participate in cell death, in addition 
to its more widely accepted role in enhanc-
ing the regeneration of the injured seg-
ments of the kidney2 or mediating survival 
during oxidative stress in vitro.3
The EGFR is present in the proximal 
tubules of the kidney: it is activated dur-
ing ischemia/reperfusion injury in vivo 
and by severe oxidative stress in vitro, 
with both conditions resulting in necrotic 
death.4 By contrast, moderate oxidative 
stress-induced EGFR activation is linked 
to cell survival.4 Cisplatin also activates 
the EGFR in renal proximal tubular 
cells in vitro, and the activated recep-
tor is involved in cell death rather than 
survival under these conditions.5 These 
studies suggest dual roles of the EGFR: 
the activated EGFR promotes either sur-
vival or death depending on either the 
intensity or the duration of stress or the 
particular stress involved; the outcome 
of EGFR activation is molded by down-
stream signaling events that depend on 
the type or intensity of the stress.
How does this dual role of the 
activated EGFR occur? EGFR-mediated 
survival signaling involves activation of 
ras and extracellular signal-regulated 
kinase (ERK)3 and their downstream 
target the transcription factor cAMP-
responsive element-binding protein 
(CREB)4 in renal epithelial cells in vitro. 
One possibility is the activation of paral-
lel signaling events; the balance between 
those signaling events determines 
whether cells survive or die. In the study 
by Sarro et al.,1 CsA treatment activated 
both ERK and phosphatidylinositol-3′-
kinase (PI3K) in an EGFR-dependent 
manner; however, only the activated 
PI3K was associated with cell death. 
Because the activated ERK generally 
participates in survival signaling during 
stress conditions,6 it is plausible that the 
pro-death pathway is supported over the 
pro-survival ERK by CsA. It is unclear, 
though, whether the activated ERK is 
indeed pro-survival in this model. Many 
studies suggest another somewhat simi-
lar scenario, that a balance between spe-
ciﬁc members of the mitogen-activated 
protein kinase (MAPK) family deter-
mines cell fate; unopposed activation 
of c-Jun NH2-terminal kinase (JNK) 
during ischemia/reperfusion injury 
in vivo7 or H2O2-mediated oxidative 
stress in vitro8 is linked to cell death. By 
contrast, the presence of activated ERK 
favors survival even in the presence of 
death signals, that is, JNK activation. 
Opposing roles of diﬀerent MAPKs in 
survival or death during stress are well 
established.6
Another possibility is that the acti-
vated EGFR is uncoupled from its 
downstream components by parallel 
signaling events, resulting in inhibition 
of survival signaling and subsequent cell 
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Figure 1 | Interacting pathways that attenuate the EGFR-mediated survival signaling during 
stress. During survival signaling, the activated EGFR stimulates CREB-mediated transcription 
through ras and ERK. Depending on the type and/or intensity of the stress signals (1) increased 
histone deacetylation inhibits CREB-mediated transcription, and cells die; or (2) increased 
activation of STAT3 or p66shc uncouples ras activation from the activated EGFR, leading to cell 
death. In both cases survival signaling is attenuated. The activated STAT3/p66shc can also directly 
participate in cell death. Stress signals also increase activity of pathways (JNK, PI3K, etc.) that are 
directly linked to cell death. The balance between pro-survival and pro-death signals determines 
cell fate. EGFR, epidermal growth factor receptor; HDAC, histone deacetylase; ERK, extracellular 
signal-regulated kinase; CREB, cAMP-responsive element-binding protein; STAT3, signal transducer 
and activator of transcription-3; p66shc, 66-kilodalton isoform of src homology 2/α-collagen-
related protein A; JNK, c-Jun NH2-terminal kinase; PI3K, phosphatidylinositol-3′-kinase.
death. For instance, the transcription 
factor signal transducer and activator 
of transcription-3 (STAT3) is known to 
bind to the activated EGFR at a phospho-
tyrosine residue that is also important for 
binding of growth factor receptor bind-
ing protein-2 (Grb2). Grb2 binding is 
essential to recruit the son-of-sevenless 
(SOS1) adaptor protein, which in turn 
brings the p21ras to the cell membrane 
and activates it. In this model, the acti-
vated STAT3 might compete with Grb2 
for EGFR binding, resulting in termina-
tion of EGFR-mediated ras/ERK signal-
ing. STAT3 activation has been observed 
during inﬂammatory conditions in many 
organs, which is also a hallmark of acute 
renal injury. Indeed, we demonstrated 
STAT3 activation in the kidneys of mice 
that underwent ischemia/reperfusion 
injury.9 We also established that inhibi-
tion of the activated STAT3 during oxida-
tive stress in renal tubules restored ERK 
activation and consequently increased 
cell survival in vitro.9
Another possibility is related to the src 
homology 2/α-collagen-related protein 
A (shcA) adaptor proteins that were 
shown to bind to a variety of receptors, 
including the EGFR, and couple those 
receptors to activation of ras and ERK. 
The shcA gene encodes three diﬀerent 
proteins: the lower-molecular weight 
(46- and 52-kilodalton) isoforms are 
generated by diﬀerential splicing, and 
the higher-molecular weight isoform 
(p66shc) is generated by differential 
promoter usage. It has been demon-
strated that the tyrosine-phosphor-
ylated p46 and p52shc shcA isoforms 
couple the activated EGFR to ras/ERK 
activation during growth factor stimula-
tion. However, stress conditions (ultra-
violet, H2O2) may also lead to tyrosine 
phosphorylation of the 66-kDa isoform, 
which inhibits downstream signaling 
from the activated EGFR.10
In some cases, however, even the fully 
executed EGFR/ras/ERK/CREB pathway 
may not execute a pro-survival signal. 
During cisplatin nephrotoxicity, for 
example, the EGFR/ras/ERK pathway 
is activated upon cisplatin treatment 
in renal proximal tubule cells in vitro, 
yet cells die.5 In this case, we found that 
though the EGFR/ras/ERK-mediated 
CREB phosphorylation took place, 
which was demonstrated to be crucial 
for survival under oxidant conditions,4 
its transcriptional activity was actu-
ally blocked (our unpublished data). 
By inhibition of histone deacetylation, 
CREB-mediated transcription and cell 
survival could be restored in vitro.
These parallel and interacting path-
ways suggest that the activated EGFR 
could signal for survival or death 
depending on the type and intensity of 
the stress and are summarized in Figure 
1. Reestablishing the survival signaling 
by targeted manipulation of these inter-
acting pathways might oﬀer therapeutic 
means to ameliorate renal injury.
Another important message of 
the paper by Sarro et al.1 is that it is 
unlikely that a single intervention will 
be applicable to all causes of acute 
kidney injury. Rational approaches to 
intervene in the extent of renal injury 
subsequent to renal stress will depend, 
genetically, on the careful study of the 
specific signaling and transcriptional 
pathways activated by a particular 
stress that determine cell fate, including 
the demonstration of the executioner 
pathway of cell death engaged by spe-
cific toxins. Ultimately whether one or 
another element in the survival path-
way can be restored to prevent acute 
kidney injury will depend, genetically, 
on a targeted genetic manipulation of 
the pathway. We await such studies in 
the future. Nonetheless, it would appear 
that the EGFR is a crucial upstream ele-
ment in the survival and death pathway 
for a wide variety of clinically relevant 
nephrotoxins. It is a good start.
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Innate immunity as a driving 
force in renal disease
E de Heer1 and DJM Peters2
Mrug et al. propose that innate immunity is a hallmark of progressive 
polycystic kidney disease (PKD). We propose that innate immunity 
is a driving force in the progression of many renal diseases. 
Renal epithelial cells are capable of expressing a large variety of 
proinflammatory genes resulting in the production of cytokines, 
chemokines, cell-adhesion molecules, and complement components. 
We suggest that future therapeutic interventions should be directed 
toward control of innate immunity in renal disease.
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Innate immunity plays a prominent role 
in many renal diseases. In teleost ﬁsh such 
as the sea lamprey and the rainbow trout, 
the anterior kidney functions as a second-
ary lymphoid organ.1 In mammalian spe-
cies, functional evolution of the kidney 
has developed in a diﬀerent direction: 
sorting of cells, proteins, electrolytes, 
and fluids. Remnants of our common 
vertebrate evolutionary past, however, 
are still present in human kidneys, as a 
multitude of proinﬂammatory genes can 
be activated in renal parenchyma.
Renal cells are capable of expressing 
Toll-like receptors2 with subsequent 
activation of mitogen-activated pro-
tein kinases, nuclear factor-κB, and 
activator protein-1 (Figure 1). Pathogen 
recognition receptors such as the Toll-
like receptors expressed by renal epi-
thelial cells contribute not only to the 
exacerbation of infection-mediated 
renal disease, but also to the self-per-
petuation of lupus nephritis by recog-
nition of nucleosomal autoantigens. 
Renal cells are also reported to express 
receptors for complement components.3 
Upon activation by proinﬂammatory 
cytokines such as interleukin-1β or 
interleukin-2, renal cells have been 
reported to express receptors for C3a, 
C3b, and C1q, resulting in the attrac-
tion, adhesion, and activation of inﬂam-
matory cells. Furthermore, renal cells 
have been shown to express costimu-
lation molecules for T-cell activation.4 
These transmembrane proteins are 
required for eﬀective activation of the 
CD3–T-cell receptor complex on both 
cytotoxic and helper T cells. Expression 
of B7 isoforms (CD80/86), inducible T-
cell co-stimulator ligand,  and CD40 has 
been described on renal epithelial cells, 
on mesangial cells, and on glomeru-
lar endothelial cells, with a profound 
impact on the course of transplant 
rejection. The above-mentioned mul-
titude of outside-in signaling by these 
receptors on epithelial cells results in 
the production of a variety of inﬂam-
matory cytokines and chemokines,5 
which attract inﬂammatory cells and 
subsequently amplify the inﬂammatory 
response in the kidney. Last but not 
least, both inﬂammation-activated and 
CD40L-activated renal cells have been 
demonstrated to produce complement 
components such as C3 (ref. 6), which 
seem more important in the course of 
renal disease than systemic production 
by the liver, as shown by elegant kidney 
transplantation experiments in C3-deﬁ-
cient mice by Pratt et al.7
With these factors, renal cells actively 
participate in the inﬂammatory response 
rather than responding to it. The pro-
pensity of renal cells to participate in 
immune responses is one of the limita-
tions encountered in kidney transplanta-
tion, in which human leukocyte antigen 
matching and prevention of ischemic 
injury are crucial for graft outcome.
The study by Mrug et al.8 (this issue) 
shows that innate immunity is also 
involved in the progression of polycystic 
kidney disease (PKD). Genome-wide 
expression analysis was performed in 
cpk mice, carrying a genetic mutation 
in the gene encoding the cilia-associ-
ated protein cystin, a model for reces-
sive polycystic disease. In severely as 
compared with mildly aﬀected animals, 
preferential upregulation was found of 
genes expressed by type II activated 
macrophages. In addition, increased 
levels of complement component C3 
were found both in cyst-lining and in 
non-cystic epithelia. It seems unlikely 
that the involvement of innate immunity 
remains conﬁned to the recessive form 
of polycystic disease. Both recessive 
